Topical CpG Enhances the Response of Murine Malignant Melanoma to Dacarbazine
- 1 September 2008
- journal article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 128 (9), 2204-2210
- https://doi.org/10.1038/jid.2008.59
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma LesionsJournal of Investigative Dermatology, 2007
- Development of TLR9 agonists for cancer therapyJCI Insight, 2007
- Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanomaBritish Journal of Dermatology, 2007
- Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell VaccineCancer Research, 2006
- Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primatesThe Journal of Experimental Medicine, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell PrecursorsAnnual Review of Immunology, 2005
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Mechanisms of hepatotoxicity caused by dacarbazine in ratsZeitschrift für Krebsforschung und Klinische Onkologie, 1993